v2.4.0.8

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (USD $)	3 Months Ended
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (USD $)	Jun. 30, 2013	Jun. 30, 2012
Revenue	$ 750,566	$ 0
Cost of sales	379,033	0
Gross Profit	371,533	0
Operating expenses:
General and administrative expenses	153,949	503,593
Depreciation and amortization expenses	76,129	91,238
Selling expenses	6,354	19,066
Total operating expenses	236,432	613,897
Operating income(loss)	135,101	(613,897)
Other income(expenses):
Interest expense, net of interest income	(12,551)	25
Other income	24,184	0
Other expense	(24,750)	0
Total other income(expenses)	(13,117)	25
Income(loss) before income tax	121,984	(613,872)
Income tax expense(credit)	42,499	(130,162)
Net Income(loss)	79,485	(483,710)
Other Comprehensive income
Foreign Currency Translation adjustment	313,346	233,824
Comprehensive income(loss)	$ 392,831	$ (249,886)
Basic and diluted income(loss) per share (in dollars per share)	$ 0.01	$ (0.04)
Basic and diluted weighted average shares outstanding (in shares)	14,728,111	13,370,968

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

Tongli Pharmaceuticals (USA), Inc. 10-Q